Send to

Choose Destination
See comment in PubMed Commons below
Haematologica. 2006 Oct;91(10):1438-40. Epub 2006 Sep 7.

Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.


This study investigated the use of low dose methotrexate (MTX) (5 mg/m2/infusion) for the treatment of graft-versus-host disease (GVHD), after failure of corticosteroids. Twelve patients had refractory acute GVHD, while eight received MTX for severe chronic GVHD and/or the side effects of corticosteroids. Thirteen patients responded to MTX with six complete remissions and little toxicity, suggesting that low dose MTX is beneficial in refractory GVHD and deserves further investigations.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center